When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Papillary urothelial neoplasm of low malignant potential

   en.wikipedia.org/wiki/Papillary_urothelial...

   Papillary urothelial neoplasm of low malignant potential (PUNLMP) is an exophytic (outward growing), (microscopically) nipple-shaped (or papillary) pre-malignant growth of the lining of the upper genitourinary tract (the urothelium), which includes the renal pelvis, ureters, urinary bladder and part of the urethra.

3. Bladder cancer - Wikipedia

   en.wikipedia.org/wiki/Bladder_cancer

   Bladder cancer is most common in wealthier regions of the world, where exposure to certain carcinogens is highest. It is also common in places where schistosome infection is common, such as North Africa. [56] Bladder cancer is much more common in men than women; around 1.1% of men and 0.27% of women develop bladder cancer. [2]

4. Transitional cell carcinoma - Wikipedia

   en.wikipedia.org/wiki/Transitional_cell_carcinoma

   It accounts for 95% of bladder cancer cases and bladder cancer is in the top 10 most common malignancy disease in the world and is associated with approximately 200,000 deaths per year in the US. [2] [3] It is the second most common type of kidney cancer, but accounts for only five to 10 percent of all primary renal malignant tumors. [4]

5. FDA approves bladder cancer treatment by Culver City company

   www.aol.com/news/fda-approves-bladder-cancer...

   For premium support please call: 800-290-4726 more ways to reach us

6. Invasive urothelial carcinoma - Wikipedia

   en.wikipedia.org/wiki/Invasive_urothelial_carcinoma

   It is a type of cancer that develops in the urinary system: the kidney, urinary bladder, and accessory organs. Transitional cell carcinoma is the most common type of bladder cancer and cancer of the ureter, urethra, renal pelvis, the ureters, the bladder, and parts of the urethra and urachus.

7. Nadofaragene firadenovec - Wikipedia

   en.wikipedia.org/wiki/Nadofaragene_firadenovec

   The safety and effectiveness of nadofaragene firadenovec was evaluated in a multicenter clinical study (Study CS-003 (NCT02773849)) that included 157 participants with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response.